Navigation Links
Codexis Expands Pharmaceutical Manufacturing Partnerships
Date:2/17/2010

REDWOOD CITY, Calif., Feb. 17 /PRNewswire/ -- Codexis, Inc. today announced two separate collaborations in pharmaceutical manufacturing with Dishman Pharmaceuticals and Chemicals and AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation. These agreements expand the application of Codexis technology to a broadened pipeline of branded innovator pharmaceutical products.

Under the new agreements, Codexis will apply its proprietary biocatalyst technology to selected therapeutic products in the collaborators' portfolios to reduce cost, increase manufacturing efficiency and lessen environmental impact.  Codexis technology is used at innovator pharmaceutical companies to enable cost-effective manufacturing processes at commercial scale.

Dishman, headquartered in Ahmedabad, India, is a global outsourcing partner manufacturing active pharmaceutical ingredients (APIs) and intermediates for the pharmaceutical industry.  Dishman operates 12 API and intermediate production facilities in India, China, Switzerland and the UK manufacturing products for leading global innovator drug companies worldwide.  Under the terms of the agreement, Codexis and Dishman will work exclusively to supply intermediates and active ingredients manufactured using Codexis technology to a select group of innovators; Dishman will be Codexis' preferred CMO partner for new opportunities at other innovators.  

AFC, headquartered in Rancho Cordova, CA, is a custom manufacturer of pharmaceutical fine chemicals.  The company specializes in technology using high energetic chemistry and other specific technologies which are advantageous for certain classes of products.  

"These new partnerships bring Codexis technology to an expanded portfolio of innovator pharmaceutical products.  They will be important as we continue to serve our pharmaceutical customers worldwide," said Alan Shaw, Ph.D., President and Chief Executive Officer.

Codexis, Inc. is a leading provider of optimized biocatalysts that make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale.  Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. 

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.

SOURCE Codexis, Inc.

RELATED LINKS
http://www.codexis.com

'/>"/>

SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Codexis Names Fernando Valle Research Fellow
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. Codexis Expands Collaboration with Teva
4. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Cellectar Expands Clinical Management Team
7. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
8. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
9. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
10. PAREXEL Expands Global Clinical Pharmacology Capabilities
11. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC ) today ... ended March 31, 2017, and raised its outlook ... guidance reflect the contribution from the Mortara Instrument ... 14, 2017.  For the fiscal second ... share compared to $0.33 per diluted share in ...
(Date:4/26/2017)... Phoenix Marketing Solutions ( Phoenix ) ... mission of transforming science into clinical practice. During a time ... innovative approach supports the life sciences industry by ... in science and medicine — which ultimately improves lives. ... 2002 by Tracy Doyle and Angela Fiordilino ...
(Date:4/25/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... management team will host a conference call and webcast before the ... The dial-in number to access the call is U.S./ Canada ... 6086379. Please dial in 10 minutes prior to the scheduled start ... call will be available from May 9, 2017 at 11:30 a.m. ...
Breaking Medicine Technology:
(Date:4/28/2017)... Abilene, Texas (PRWEB) , ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... says, reveals which name the Creator responds to and which He does not. Yisrayl ... to believe which one is the true name, but he says with a little Scripture, ...
(Date:4/28/2017)... LAKE CITY, UTAH (PRWEB) , ... April 28, ... ... Côté as Account Manager for the North East region. Côté has 20+ years ... and consulting. Prior to Phytomer, Côté worked with an array of high-end cosmetic ...
(Date:4/28/2017)... New York (PRWEB) , ... April 28, 2017 ... ... anti-aging skincare and advanced nutraceutical supplements, through its Nova Skin Sciences ... provides the hydrating benefits of a moisturizer with the power of an anti-aging ...
(Date:4/28/2017)... ... ... Lowe is a popular actor that has been in many different movies and television ... host of the “Informed” series. The program focuses on many important issues that society ... thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, people still ...
(Date:4/28/2017)... ... 28, 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Braun Medical Inc. , a leader in infusion therapy and pain management. , ... 90 percent of hospital patients receiving a peripheral IV catheter as part of their ...
Breaking Medicine News(10 mins):